Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Chronic Heart Failure

Free Subscription Articles published in J Mol Cell Cardiol Retrieve available abstracts of 74 articles: HTML format

Single Articles

November 2023
1. CHEN S, Wang K, Wang J, Chen X, et al
   Profiling cardiomyocytes at single cell resolution reveals COX7B could be a potential target for attenuating heart failure in cardiac hypertrophy.
   J Mol Cell Cardiol. 2023;186:45-56.
   PubMed     Abstract available
   
   
   October 2023
2. WADDELL HMM, Mereacre V, Alvarado FJ, Munro ML, et al
   Clustering properties of the cardiac ryanodine receptor in health and heart failure.
   J Mol Cell Cardiol. 2023;185:38-49.
   PubMed     Abstract available
   
   
   
3. ZHAO C, Jiang X, Peng L, Zhang Y, et al
   Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids.
   J Mol Cell Cardiol. 2023;185:13-25.
   PubMed     Abstract available
   
   
   
4. MENASCHE P
   Human PSC-derived cardiac cells and their products: therapies for cardiac repair.
   J Mol Cell Cardiol. 2023;183:14-21.
   PubMed     Abstract available
   
   
   September 2023
5. LIU Z, Liu Z, Xu X, Zhou Y, et al
   Role of ventrolateral part of ventromedial hypothalamus in post-myocardial infarction cardiac dysfunction induced by sympathetic nervous system.
   J Mol Cell Cardiol. 2023 Sep 30:S0022-2828(23)00154.
   PubMed     Abstract available
   
   
   
6. PEZHOUMAN A, Nguyen NB, Kay M, Kanjilal B, et al
   Cardiac regeneration - Past advancements, current challenges, and future directions.
   J Mol Cell Cardiol. 2023;182:75-85.
   PubMed     Abstract available
   
   
   August 2023
7. KMIETCZYK V, Oelschlager J, Gupta P, Varma E, et al
   Ythdf2 regulates cardiac remodeling through its mRNA target transcripts.
   J Mol Cell Cardiol. 2023;181:57-66.
   PubMed     Abstract available
   
   
   July 2023
8. KOBAYASHI S, Yamamoto T, Yano M
   RyR2-stabilization therapy with dantrolene against left ventricular remodeling and lethal arrhythmia in heart failure.
   J Mol Cell Cardiol. 2023 Jul 5:S0022-2828(23)00108.
   PubMed    
   
   
   June 2023
9. MONTANES-AGUDO P, Pinto YM, Creemers EE
   Splicing factors in the heart: Uncovering shared and unique targets.
   J Mol Cell Cardiol. 2023;179:72-79.
   PubMed     Abstract available
   
   
   May 2023
10. YAMADA Y, Sadahiro T, Ieda M
    Development of direct cardiac reprogramming for clinical applications.
    J Mol Cell Cardiol. 2023;178:1-8.
    PubMed     Abstract available
    
    
    April 2023
11. MEHDIPOUR M, Park S, Huang GN
    Unlocking cardiomyocyte renewal potential for myocardial regeneration therapy.
    J Mol Cell Cardiol. 2023;177:9-20.
    PubMed     Abstract available
    
    
    
12. LI R, Xiang C, Li Y, Nie Y, et al
    Targeting immunoregulation for cardiac regeneration.
    J Mol Cell Cardiol. 2023;177:1-8.
    PubMed     Abstract available
    
    
    March 2023
13. GARRY GA, Olson EN
    Reprogramming of cardiac cell fate as a therapeutic strategy for ischemic heart disease.
    J Mol Cell Cardiol. 2023 Mar 28:S0022-2828(23)00058.
    PubMed     Abstract available
    
    
    
14. FUJII S, Kobayashi S, Chang Y, Nawata J, et al
    RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
    J Mol Cell Cardiol. 2023 Mar 22:S0022-2828(23)00052.
    PubMed     Abstract available
    
    
    January 2023
15. ZHANG J, Song Y, Li Y, Lin HB, et al
    Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications.
    J Mol Cell Cardiol. 2023;174:15-24.
    PubMed     Abstract available
    
    
    
16. KHALILIMEYBODI A, Riaz M, Campbell SG, Omens JH, et al
    Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy.
    J Mol Cell Cardiol. 2023;174:1-14.
    PubMed     Abstract available
    
    
    December 2022
17. ABOUMSALLEM JP, Shi C, De Wit S, Markousis-Mavrogenis G, et al
    Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies.
    J Mol Cell Cardiol. 2022;175:13-28.
    PubMed     Abstract available
    
    
    
18. DELBRIDGE LMD, Bell JR, Weeks KL, Raaijmakers AJA, et al
    HFpEF etiology - Can focus on sex-specific mechanisms deliver insights for all?
    J Mol Cell Cardiol. 2022;173:71-72.
    PubMed    
    
    
    
19. NAH J, Zablocki D, Sadoshima J
    The role of autophagic cell death in cardiac disease.
    J Mol Cell Cardiol. 2022;173:16-24.
    PubMed     Abstract available
    
    
    November 2022
20. GARRY DJ, Weiner JI, Greising SM, Garry MG, et al
    Mechanisms and strategies to promote cardiac xenotransplantation.
    J Mol Cell Cardiol. 2022;172:109-119.
    PubMed     Abstract available
    
    
    
21. FOWLER ED, Wang N, Hezzell MJ, Chanoit G, et al
    Improved Ca(2+) release synchrony following selective modification of Itof and phase 1 repolarization in normal and failing ventricular myocytes.
    J Mol Cell Cardiol. 2022;172:52-62.
    PubMed     Abstract available
    
    
    October 2022
22. YANG X, Kawasaki NK, Min J, Matsui T, et al
    Ferroptosis in heart failure.
    J Mol Cell Cardiol. 2022 Oct 20. pii: S0022-2828(22)00537.
    PubMed     Abstract available
    
    
    
23. HUNTER JD, Hancko A, Shakya P, Hill R, et al
    Characterization of decellularized left and right ventricular myocardial matrix hydrogels and their effects on cardiac progenitor cells.
    J Mol Cell Cardiol. 2022;171:45-55.
    PubMed     Abstract available
    
    
    September 2022
24. JOHNSON DM, Pavlovic D
    What is actually preserved in HFpEF? Focus on myocyte calcium handling remodelling.
    J Mol Cell Cardiol. 2022;170:115-116.
    PubMed    
    
    
    
25. ZHU W, Sun J, Bishop SP, Sadek H, et al
    Turning back the clock: A concise viewpoint of cardiomyocyte cell cycle activation for myocardial regeneration and repair.
    J Mol Cell Cardiol. 2022;170:15-21.
    PubMed     Abstract available
    
    
    August 2022
26. FU J, Li L, Chen L, Su C, et al
    PGE2 protects against heart failure through inhibiting TGF-beta1 synthesis in cardiomyocytes and crosstalk between TGF-beta1 and GRK2.
    J Mol Cell Cardiol. 2022;172:63-77.
    PubMed     Abstract available
    
    
    
27. THARP CA, McKinsey TA
    Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF.
    J Mol Cell Cardiol. 2022;169:111-112.
    PubMed    
    
    
    
28. GUO X, Chen Y, Liu Q
    Necroptosis in heart disease: Molecular mechanisms and therapeutic implications.
    J Mol Cell Cardiol. 2022;169:74-83.
    PubMed     Abstract available
    
    
    
29. GHEBLAWI M, de Oliveira AA, Williams VR, John R, et al
    An advanced endothelial murine HFpEF model: eNOS is critical for angiotensin 1-7 rescue of the diabetic phenotype.
    J Mol Cell Cardiol. 2022;169:10-12.
    PubMed    
    
    
    July 2022
30. FERRERO KM, Koch WJ
    GRK2 in cardiovascular disease and its potential as a therapeutic target.
    J Mol Cell Cardiol. 2022;172:14-23.
    PubMed     Abstract available
    
    
    
31. MARTENS P, Nguyen C, Tang WHW
    Is epicardial adipose tissue a key pathophysiologic target in heart failure with preserved ejection?
    J Mol Cell Cardiol. 2022;171:69-70.
    PubMed    
    
    
    
32. BODE D, Sotomayor-Flores C, Schiattarella GG
    Up next: The dawn of systems biology in HFpEF research.
    J Mol Cell Cardiol. 2022;168:96-97.
    PubMed    
    
    
    
33. WITHAAR C, Li S, Meems LMG, Sillje HHW, et al
    Aging and HFpEF: Are we running out of time?
    J Mol Cell Cardiol. 2022;168:33-34.
    PubMed    
    
    
    
34. VALERO-MUNOZ M, Sam F
    A misdirected conundrum in translational HFpEF research.
    J Mol Cell Cardiol. 2022;168:1-2.
    PubMed    
    
    
    June 2022
35. WEERTS J, Mourmans SGJ, Eringa E, van Empel VPM, et al
    Improving insights into the heterogeneous HFpEF syndrome through microvascular research.
    J Mol Cell Cardiol. 2022;167:106-108.
    PubMed    
    
    
    
36. EMTER CA
    A 'Swine Time' for HFpEF: Multiple animal models for a myriad of clinical phenotypes.
    J Mol Cell Cardiol. 2022;167:15-16.
    PubMed    
    
    
    May 2022
37. CHENG G, Zhu D, Huang K, Caranasos TG, et al
    Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure.
    J Mol Cell Cardiol. 2022 May 3. pii: S0022-2828(22)00085.
    PubMed     Abstract available
    
    
    
38. KANASSATEGA RS, Bunch TA, Lepak VC, Wang C, et al
    Human cardiac myosin-binding protein C phosphorylation- and mutation-dependent structural dynamics monitored by time-resolved FRET.
    J Mol Cell Cardiol. 2022;166:116-126.
    PubMed     Abstract available
    
    
    
39. ZHAO Y, Godier-Furnemont A, Bax NAM, Bouten CVC, et al
    Changes in extracellular matrix in failing human non-ischemic and ischemic hearts with mechanical unloading.
    J Mol Cell Cardiol. 2022;166:137-151.
    PubMed     Abstract available
    
    
    April 2022
40. SEDEJ S, Abdellatif M
    Metabolic therapy for managing heart failure with preserved ejection fraction.
    J Mol Cell Cardiol. 2022;168:68-69.
    PubMed    
    
    
    
41. MOTURI S, Ghosh-Choudhary SK, Finkel T
    Cardiovascular disease and the biology of aging.
    J Mol Cell Cardiol. 2022;167:109-117.
    PubMed     Abstract available
    
    
    
42. WANG C, Zhang Y, Methawasin M, Braz CU, et al
    RBM20(S639G) mutation is a high genetic risk factor for premature death through RNA-protein condensates.
    J Mol Cell Cardiol. 2022;165:115-129.
    PubMed     Abstract available
    
    
    March 2022
43. GARBINCIUS JF, Luongo TS, Jadiya P, Hildebrand AN, et al
    Enhanced NCLX-dependent mitochondrial Ca(2+) efflux attenuates pathological remodeling in heart failure.
    J Mol Cell Cardiol. 2022;167:52-66.
    PubMed     Abstract available
    
    
    
44. ABDELLATIF M, Kroemer G
    Heart failure with preserved ejection fraction: An age-related condition.
    J Mol Cell Cardiol. 2022;167:83-84.
    PubMed    
    
    
    
45. DYCK JRB, Sossalla S, Hamdani N, Coronel R, et al
    Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    J Mol Cell Cardiol. 2022;167:17-31.
    PubMed     Abstract available
    
    
    
46. WANG YL, Bai L, Shi XR, Zhu H, et al
    Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.
    J Mol Cell Cardiol. 2022 Mar 18. pii: S0022-2828(22)00047.
    PubMed     Abstract available
    
    
    
47. QIU Y, Pan X, Chen Y, Xiao J, et al
    Hallmarks of exercised heart.
    J Mol Cell Cardiol. 2022;164:126-135.
    PubMed     Abstract available
    
    
    
48. WANG N, Dries E, Fowler ED, Harmer SC, et al
    Inducing Ito,f and phase 1 repolarization of the cardiac action potential with a Kv4.3/KChIP2.1 bicistronic transgene.
    J Mol Cell Cardiol. 2022;164:29-41.
    PubMed     Abstract available
    
    
    
49. TANI H, Tohyama S, Kishino Y, Kanazawa H, et al
    Production of functional cardiomyocytes and cardiac tissue from human induced pluripotent stem cells for regenerative therapy.
    J Mol Cell Cardiol. 2022;164:83-91.
    PubMed     Abstract available
    
    
    February 2022
50. ESCHENHAGEN T, Ridders K, Weinberger F
    How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes.
    J Mol Cell Cardiol. 2022;163:106-117.
    PubMed     Abstract available
    
    
    
51. STENZIG J, Lemoine MD, Stoter AMS, Wrona KM, et al
    Recapitulation of dyssynchrony-associated contractile impairment in asymmetrically paced engineered heart tissue.
    J Mol Cell Cardiol. 2022;163:97-105.
    PubMed     Abstract available
    
    
    January 2022
52. LIU X, Zhang Y, Deng Y, Yang L, et al
    Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice.
    J Mol Cell Cardiol. 2022;165:76-85.
    PubMed     Abstract available
    
    
    November 2021
53. CHAPSKI DJ, Cabaj M, Morselli M, Mason RJ, et al
    Early adaptive chromatin remodeling events precede pathologic phenotypes and are reinforced in the failing heart.
    J Mol Cell Cardiol. 2021;160:73-86.
    PubMed     Abstract available
    
    
    October 2021
54. CAGGIANO LR, Holmes JW, Witzenburg CM
    Individual variability in animal-specific hemodynamic compensation following myocardial infarction.
    J Mol Cell Cardiol. 2021 Oct 28. pii: S0022-2828(21)00207.
    PubMed     Abstract available
    
    
    September 2021
55. DAVIS K, Azarcon P, Hickenlooper S, Bia R, et al
    The role of demethylases in cardiac development and disease.
    J Mol Cell Cardiol. 2021;158:89-100.
    PubMed     Abstract available
    
    
    
56. SHEN S, Sewanan LR, Campbell SG
    Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
    J Mol Cell Cardiol. 2021;158:11-25.
    PubMed     Abstract available
    
    
    
57. RITTERHOFF J, McMillen TS, Villet O, Young S, et al
    Increasing fatty acid oxidation elicits a sex-dependent response in failing mouse hearts.
    J Mol Cell Cardiol. 2021;158:1-10.
    PubMed     Abstract available
    
    
    August 2021
58. AKSENTIJEVIC D, Shattock MJ
    With a grain of salt: Sodium elevation and metabolic remodelling in heart failure.
    J Mol Cell Cardiol. 2021 Aug 6. pii: S0022-2828(21)00156.
    PubMed     Abstract available
    
    
    July 2021
59. MASHALI MA, Saad NS, Canan BD, Elnakish MT, et al
    Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium.
    J Mol Cell Cardiol. 2021;156:7-19.
    PubMed     Abstract available
    
    
    June 2021
60. PATEREK A, Okninska M, Chajduk E, Polkowska-Motrenko H, et al
    Systemic iron deficiency does not affect the cardiac iron content and progression of heart failure.
    J Mol Cell Cardiol. 2021;159:16-27.
    PubMed     Abstract available
    
    
    
61. GARNIER A, Bork NI, Jacquet E, Zipfel S, et al
    Mapping genetic changes in the cAMP-signaling cascade in human atria.
    J Mol Cell Cardiol. 2021;155:10-20.
    PubMed     Abstract available
    
    
    May 2021
62. YAN J, Killingsworth C, Walcott G, Zhu Y, et al
    Molecular remodeling of Cx43, but not structural remodeling, promotes arrhythmias in an arrhythmogenic canine model of nonischemic heart failure.
    J Mol Cell Cardiol. 2021 May 25. pii: S0022-2828(21)00106.
    PubMed     Abstract available
    
    
    
63. IGAKI Y, Tanno M, Sato T, Kouzu H, et al
    Xanthine oxidoreductase-mediated injury is amplified by upregulated AMP deaminase in type 2 diabetic rat hearts under the condition of pressure overload.
    J Mol Cell Cardiol. 2021;154:21-31.
    PubMed     Abstract available
    
    
    
64. MCCABE KJ, Rangamani P
    Computational modeling approaches to cAMP/PKA signaling in cardiomyocytes.
    J Mol Cell Cardiol. 2021;154:32-40.
    PubMed     Abstract available
    
    
    February 2021
65. RATTKA M, Westphal S, Gahr BM, Just S, et al
    Spen deficiency interferes with Connexin 43 expression and leads to heart failure in zebrafish.
    J Mol Cell Cardiol. 2021 Feb 4. pii: S0022-2828(21)00022.
    PubMed     Abstract available
    
    
    
66. HINGER SA, Wei J, Dorn LE, Whitson BA, et al
    Remodeling of the m(6)A landscape in the heart reveals few conserved post-transcriptional events underlying cardiomyocyte hypertrophy.
    J Mol Cell Cardiol. 2021;151:46-55.
    PubMed     Abstract available
    
    
    December 2020
67. MORA MT, Gong JQX, Sobie EA, Trenor B, et al
    The role of beta-adrenergic system remodeling in human heart failure: A mechanistic investigation.
    J Mol Cell Cardiol. 2020 Dec 13. pii: S0022-2828(20)30344.
    PubMed     Abstract available
    
    
    
68. MAMIC P, Chaikijurajai T, Tang WHW
    Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.
    J Mol Cell Cardiol. 2020 Dec 8. pii: S0022-2828(20)30340.
    PubMed     Abstract available
    
    
    
69. CORTASSA S, Juhaszova M, Aon MA, Zorov DB, et al
    Mitochondrial Ca(2+), redox environment and ROS emission in heart failure: Two sides of the same coin?
    J Mol Cell Cardiol. 2020 Dec 7. pii: S0022-2828(20)30336.
    PubMed     Abstract available
    
    
    
70. O'ROURKE B, Ashok D, Liu T
    Mitochondrial Ca(2+) in heart failure: Not enough or too much?
    J Mol Cell Cardiol. 2020 Dec 5. pii: S0022-2828(20)30337.
    PubMed     Abstract available
    
    
    
71. NOMURA S, Komuro I
    Precision medicine for heart failure based on molecular mechanisms The Research Achievement Award Lecture.
    J Mol Cell Cardiol. 2020 Dec 1. pii: S0022-2828(20)30333.
    PubMed     Abstract available
    
    
    November 2020
72. ROLLE IG, Crivellari I, Zanello A, Mazzega E, et al
    Heart failure impairs the mechanotransduction propeties of human cardiac pericytes.
    J Mol Cell Cardiol. 2020;151:15-30.
    PubMed     Abstract available
    
    
    March 2020
73. RAZAVI AC, Bazzano LA, He J, Li S, et al
    Pseudouridine and N-formylmethionine associate with left ventricular mass index: Metabolome-wide association analysis of cardiac remodeling.
    J Mol Cell Cardiol. 2020;140:22-29.
    PubMed     Abstract available
    
    
    January 2020
74. ALI HR, Michel CR, Lin YH, McKinsey TA, et al
    Defining decreased protein succinylation of failing human cardiac myofibrils in ischemic cardiomyopathy.
    J Mol Cell Cardiol. 2020;138:304-317.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.